Incidence of chronic kidney disease in patients with atrial fibrillation and its relevance for prescribing new oral antithrombotic drugs

Journal of Thrombosis and Haemostasis

Volumn 9, Issue 8, 2011, Pages 1652-1653

  Kooiman, Judith ^a   van de Peppel, W R ^a   van der Meer, F J M ^a   Huisman, M V ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; DABIGATRAN ETEXILATE; NEW DRUG; RIVAROXABAN; THROMBIN INHIBITOR;

ANTICOAGULANT THERAPY; BLEEDING; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; DISEASE SEVERITY; DRUG APPROVAL; DRUG EXCRETION; FOOD AND DRUG ADMINISTRATION; GLOMERULUS FILTRATION RATE; HEART ATRIUM FIBRILLATION; HUMAN; KIDNEY FUNCTION; LETTER; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK BENEFIT ANALYSIS; STROKE; THROMBOSIS;

ADMINISTRATION, ORAL; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; BIOLOGICAL MARKERS; CHRONIC DISEASE; CREATININE; FIBRINOLYTIC AGENTS; GLOMERULAR FILTRATION RATE; HUMANS; INCIDENCE; KIDNEY; KIDNEY DISEASES; MORPHOLINES; NETHERLANDS; PATIENT SELECTION; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; THIOPHENES;

EID: 80051579089     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2011.04347.x     Document Type: Letter

References (12)

1. Stangier J, Stähle H, Rathgen K, Roth W, Shakeri-Nejad K. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 2008; 47: 285-95.
2. Stangier J, Rathgen K, Stähle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 2010; 49: 259-68.
3. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Poque J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius HC, Joyner CD, Wallentin L. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-51.
4. ROCKET AF Study Investigators. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J 2010; 159: 340-7.
5. Iguchi Y, Kimura K, Kobayashi K, Aoki J, Terasawa Y, Sakai K, Uemura J, Shibazaki K. Relation of atrial fibrillation to glomerular filtration rate. Am J Cardiol 2008; 102: 1056-9.
6. Cozma D, Popescu BA, Lighezan D, Lucian P, Mornos C, Ginghina C, Dragulescu SI. Left atrial remodeling: assessment of size and shape to detect vulnerability to atrial fibrillation. Pacing Clin Electrophysiol 2007; 30 (Suppl. 1): S147-50.
7. Beasley N, Thompson A. Clinical Review dabigatran ND 22-512. 2011.
8. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: S1-266.
9. Reinecke H, Brand E, Mesters R, Schäbitz WR, Fisher M, Pavenstädt H, Breithardt G. Dilemmas in the management of atrial fibrillation in chronic kidney disease. J Am Soc Nephrol 2009; 20: 705-11.
10. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW, Van Lente F. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006; 145: 247-54.
11. Van Pottelbergh G, Van Heden L, Matheï C, Degryse J. Methods to evaluate renal function in elderly patients: a systematic literature review. Age Ageing 2010; 39: 542-8.
12. Go AS, Fang MC, Udaltsova N, Chang Y, Pomernacki NK, Borowsky L, Singer DE. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation 2009; 119: 1363-9.